Nicholas S. Akins

Nicholas S. Akins

Auto-generated profile, based on publicly available information

Nicholas S. Akins

Department of Chemistry

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2018 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
NANicholas S. Akins
Nicholas S. Akins
TNTanner C. Nielson
Tanner C. Nielson
HLHoang V. Le
Hoang V. Le
Cancer cells have a very different metabolism from that of normal cells from which they are derived. Their metabolism is elevated, which allows them to sustain higher proliferative rate and resist some cell death signals. This phenomenon, known as the “Warburg effect”, has become the focus of intensive efforts in the discovery of new therapeutic targets and new cancer drugs. Both glycolysis and glutaminolysis pathways are enhanced in cancer cells. While glycolysis is enhanced to satisfy the increasing energy demand of cancer cells, glutaminolysis is enhanced to provide biosynthetic precursors for cancer cells. It was recently discovered that there is a tyrosine phosphorylation of a specific isoform of pyruvate kinase, the M2 isoform, that is preferentially expressed in all cancer cells, which results in the generation of pyruvate through a unique enzymatic mechanism that is uncoupled from ATP production. Pyruvate produced through this unique enzymatic mechanism is converted primarily into lactic acid, rather than acetyl-CoA for the synthesis of citrate, which would normally then enter the citric acid cycle. Inhibition of key enzymes in glycolysis and glutaminolysis pathways with small molecules has provided a novel but emerging area of cancer research and has been proven effective in slowing the proliferation of cancer cells, with several inhibitors being in clinical trials. This review paper will cover recent advances in the development of chemotherapeutic agents against several metabolic targets for cancer therapy, including glucose transporters, hexokinase, pyruvate kinase M2, glutaminase, and isocitrate dehydrogenase.

13 February 2023 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
LHLynnea D. Harris
Lynnea D. Harris
MRMichael C. Regan
Michael C. Regan
SMScott J. Myers
Scott J. Myers
KNKelsey A. Nocilla
Kelsey A. Nocilla
NANicholas S. Akins
Nicholas S. Akins
Dennis LiottaDennis Liotta
Dennis Liotta
Many cases of accidental death associated with drug overdose are due to chronic opioid use, tolerance, and addiction. Analgesic tolerance is characterized by a decreased response to the analgesic effects of opioids, requiring increasingly higher doses to maintain the desired level of pain relief. Overactivation of GluN2B-containing N-methyl-d-Aspartate receptors is thought to play a key role in mechanisms underlying cellular adaptation that takes place in the development of analgesic tolerance. Herein, we describe a novel GluN2B-selective negative allosteric modulator, EU93-108, that shows high potency and brain penetrance. We describe the structural basis for binding at atomic resolution. This compound possesses intrinsic analgesic properties in the rodent tail immersion test. EU93-108 has an acute and significant anodyne effect, whereby morphine when combined with EU93-108 produces a higher tail flick latency compared to that of morphine alone. These data suggest that engagement of GluN2B as a target has utility in the treatment of pain, and EU93-108 could serve as an appropriate tool compound to interrogate this hypothesis. Future structure-activity relationship work around this scaffold could give rise to compounds that can be co-administered with opioids to diminish the onset of tolerance due to chronic opioid use, thereby modifying their utility.

11 August 2023 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
MDMichael P. D’eRasmo
Michael P. D’eRasmo
NANicholas S. Akins
Nicholas S. Akins
PMPeipei Ma
Peipei Ma
YJYao Jing
Yao Jing
SSSharon A. Swanger
Sharon A. Swanger
STStephen F. Traynelis
Stephen F. Traynelis
Subunit-selective inhibition of N-methyl-d-aspartate receptors (NMDARs) is a promising therapeutic strategy for several neurological disorders, including epilepsy, Alzheimer's and Parkinson's disease, depression, and acute brain injury. We previously described the dihydroquinoline-pyrazoline (DQP) analogue 2a (DQP-26) as a potent NMDAR negative allosteric modulator with selectivity for GluN2C/D over GluN2A/B. However, moderate (<100-fold) subunit selectivity, inadequate cell-membrane permeability, and poor brain penetration complicated the use of 2a as an in vivo probe. In an effort to improve selectivity and the pharmacokinetic profile of the series, we performed additional structure-activity relationship studies of the succinate side chain and investigated the use of prodrugs to mask the pendant carboxylic acid. These efforts led to discovery of the analogue (S)-(-)-2i, also referred to as (S)-(-)-DQP-997-74, which exhibits >100- and >300-fold selectivity for GluN2C- and GluN2D-containing NMDARs (IC50 0.069 and 0.035 μM, respectively) compared to GluN2A- and GluN2B-containing receptors (IC50 5.2 and 16 μM, respectively) and has no effects on AMPA, kainate, or GluN1/GluN3 receptors. Compound (S)-(-)-2i is 5-fold more potent than (S)-2a. In addition, compound 2i shows a time-dependent enhancement of inhibitory actions at GluN2C- and GluN2D-containing NMDARs in the presence of the agonist glutamate, which could attenuate hypersynchronous activity driven by high-frequency excitatory synaptic transmission. Consistent with this finding, compound 2i significantly reduced the number of epileptic events in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy that is associated with upregulation of the GluN2C subunit. Thus, 2i represents a robust tool for the GluN2C/D target validation. Esterification of the succinate carboxylate improved brain penetration, suggesting a strategy for therapeutic development of this series for NMDAR-associated neurological conditions.

24 April 2020 in Neurochemistry International
Verified
Journal Article
Closed access
JXJihong Xu
Jihong Xu
FCFang Chen
Fang Chen
SWShuyan Wang
Shuyan Wang
NANicholas S. Akins
Nicholas S. Akins
IHImran Hossain
Imran Hossain
RLRenyu Liu
Renyu Liu

21 April 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RFRussell G. Fritzemeier
Russell G. Fritzemeier
NANicholas S. Akins
Nicholas S. Akins
PAPaul J. Arcoria
Paul J. Arcoria
SPSrinu Paladugu
Srinu Paladugu
EUElijah Z. Ullman
Elijah Z. Ullman
Dennis LiottaDennis Liotta
Dennis Liotta

10 February 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
IHImran Hossain
Imran Hossain
ATAjit G. Thomas
Ajit G. Thomas
FMFakhri Mahdi
Fakhri Mahdi
AAAmna T. Adam
Amna T. Adam
NANicholas S. Akins
Nicholas S. Akins
HLHoang V. Le
Hoang V. Le
L-γ-Methyleneglutamic acid amides selectively inhibit the growth of MCF-7 (ER+/PR+/HER2−), SK-BR-3 (ER−/PR−/HER2+), and triple negative MDA-MB-231 cancer cell lines.